The provisions for income taxes consist of the following (in thousands):

 

 

The following is a reconciliation of the federal tax calculated at the statutory rate of to the actual income taxes provided (in thousands):

 

  

The effective rate for the year ended increased by compared to the prior year. The increase was primarily due to unfavorable discrete events in fiscal related to the revaluation of contingent consideration which is a tax deductible expense.

 

The Company recognized net expense related to discrete tax items of million in fiscal including million in expense related to the revaluation of contingent consideration which is a tax deductible expense.

In the year ended as a result of the recent acquisitions, the rate reflects an increase for state tax expense as well as a resulting provision to return true-up from fiscal The increase is offset by the non-taxable gain which was a result of purchasing the remaining interest in CyVek. In addition the Company’s R&D Europe subsidiary declared and paid a dividend of million which resulted in a tax benefit of approximately million.

The effective rate for the year ended decreased by compared to the prior year. The rate decrease was primarily driven by additional R&D credit benefit due to the retroactive reinstatement of the credit under the Protecting Americans from Tax Hikes Act of an increase in the foreign rate benefit due to the reduction in the UK income tax rate and a reduction in state tax related to the prior year. These decreases were partially offset by less of a foreign tax credit benefit than in the prior year and the non-recurrence of a non-taxable gain. 

 

Temporary differences comprising deferred taxes on the Consolidated Balance Sheets are as follows (in thousands):

 

 

A deferred tax valuation allowance is required when it is more likely than that all or a portion of deferred tax assets will be realized. The valuation allowance as of was million, a decrease of million from the prior year. The decrease was driven by a decrease in the valuation allowance for the Company’s equity investments. The valuation allowance as of was million

, an increase of million over prior year. This increase included a million change related to an equity investment and was recorded through other comprehensive income and was partially offset by a decrease of million primarily related to the expiration of state net operating loss carryforwards and research and development credits. 

 

As of approximately million of the valuation allowance relates to certain foreign and state tax net operating loss and state credit carryforwards that existed at the date the Company acquired ACD, Novus, ProteinSimple and CyVek as well as immaterial amounts generated after the acquisitions. The remainder of the valuation allowance was for certain state tax credit carryovers generated or acquired in the current or prior fiscal years. Approximately million of the valuation allowance as of was for certain foreign and state tax net operating loss and state credit carryforwards that existed at the date the Company acquired Novus, ProteinSimple, and CyVek or have been generated after the acquisitions. The remainder of the valuation allowance was for certain state tax credit carryovers generated or acquired in current or prior fiscal years. The Company believes it is more likely than that these tax carryovers will be realized.

 

As of the Company has federal operating loss carryforwards of approximately million and state operating loss carryforwards of million from its acquisitions of ACD, ProteinSimple and CyVek, which are limited under IRC Section  As of the Company has foreign net operating loss carryforwards of million.

 The net operating loss carryforwards expire between fiscal and The Company has a deferred tax asset of million, net of the valuation allowance discussed above, related to the net operating loss carryovers. As of the Company has federal and state tax credit carryforwards of million and million, respectively. The federal tax credit carryforwards expire between and A majority of the state credit carryforwards have expiry date. The Company has a deferred tax asset of million, net of the valuation allowance discussed above, related to the tax credit carryovers.

 

The Company has recognized a deferred tax liability for unremitted earnings of approximately million from its foreign operations because its subsidiaries have invested or will invest the undistributed earnings indefinitely, or the earnings will be remitted in a tax-neutral transaction. Generally, such amounts become subject to United States taxation upon the remittance of dividends and under other circumstances. It is practical to estimate the amount of the deferred income tax liabilities related to investments in these foreign subsidiaries.

 

The Company's unrecognized tax benefits at and including accrued interest and penalties, were material. The Company does believe it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase in the next months. The Company files income tax returns in the U.S federal and certain state tax jurisdictions, and several jurisdictions outside the U.S. The Company's federal returns are subject to tax assessment for and subsequent years. State and foreign income tax returns are generally subject to examination for a period of to years after filing of the respective return. The state impact of any federal changes remains subject to examination by various states for a period of up to year after formal notification to the states.